Perspectives on assessing benefits and risks in clinical trials for Alzheimer's disease

Alzheimer's and Dementia

Volumn 2, Issue 3, 2006, Pages 160-163

  McConnell, Stephen ^a   Karlawish, Jason ^b   Vellas, Bruno ^c   DeKosky, Steven ^d  

^a ALZHEIMER'S ASSOCIATION   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Alzheimer Clinical and Research Center   (France)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; FDA; Public policy; Surrogate consent; Treatment risk and benefit

Indexed keywords

NOOTROPIC AGENT;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MEDICAL ETHICS; METHODOLOGY; MORALITY; PATIENT; PATIENT PARTICIPATION; POLITICS; PRIORITY JOURNAL; PUBLIC OPINION; RISK BENEFIT ANALYSIS; SCIENTIST; SOCIAL ASPECT;

EID: 33744941316     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.03.015     Document Type: Editorial

References (13)

1. Kim S.Y., Cox C.D., and Caine E.D. Impaired decision-making ability in subjects with Alzheimer's disease and willingness to participate in research. Am J Psychiatry 159 5 (2002) 797-802
2. Karlawish J.H., Casarett D.J., James B.D., Xie S.X., and Kim S.Y. The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment. Neurology 64 9 (2005) 1514-1519
3. Karlawish J.H., Casarett D.J., and James B.D. Alzheimer's disease patients' and caregivers' capacity, competency and reasons to enroll in an early phase Alzheimer's disease clinical trial. J Am Geriatr Soc 50 12 (2002) 2019-2024
4. Hirschman K.B., Xie S.X., Feudtner C., and Karlawish J.H. How does an Alzheimer's Disease patient's role in medical decision-making change over time?. J Geriatr Psychiatry Neurol 17 2 (2004) 55-60
5. Karlawish J.H., Klocinski J., Merz J., Clark C.M., and Asch D.A. Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology 55 7 (2000) 1008-1014
6. Karlawish J.H., Casarett D., Klocinski J., and Sankar P. How do AD patients and their caregivers decide whether to enroll in a clinical trial?. Neurology 56 6 (2001) 789-792
7. Weijer C., and Miller P.B. When are research risks reasonable in relation to anticipated benefits?. Nat Med 10 6 (2004) 570-573
8. Kim S.Y., and Caine E.D. Utility and limits of the Mini Mental State Examination in evaluating consent capacity in Alzheimer's disease. Psychiatr Serv 53 10 (2002) 1322-1324
9. Kim S.Y., Kim H.M., McCallum C., and Tariot P.N. What do people at risk for Alzheimer disease think about surrogate consent for research?. Neurology 65 9 (2005) 1395-1401
10. Karlawish J.H., Casarett D.J., James B.D., Tenhave T., Clark C.M., and Asch D.A. Why would caregivers not want to treat their relative's Alzheimer's disease?. J Am Geriatr Soc 51 10 (2003) 1391-1397
11. Wendler D., Martinez R.A., Fairclough D., Sunderland T., and Emanuel E. Views of potential subjects toward proposed regulations for clinical research with adults unable to consent. Am J Psychiatry 159 4 (2002) 585-591
12. Alzheimer's Association. Research consent for cognitively impaired adults. Recommendations for institutional review boards and investigators. Alzheimer Dis Assoc Disord 18 3 (2004) 171-175
13. Karlawish J.H., and Lantos J. Community equipoise and the architecture of clinical research. Camb Q Healthc Ethics 6 4 (1997) 385-396